Articles by Oliver Grant
Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease
Takeda announces positive topline results for TAK-881, showing pharmacokinetic comparability to HYQVIA in pivotal Phase 2/3 trial for PID patients.
SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026
SQ Innovation announces SUBCUT HF II trial results for Lasix ONYU, the first at-home subcutaneous furosemide treatment for heart failure edema, May 9th.
GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment
GRIN Therapeutics initiates Phase 3 Beeline study in Europe for investigational radiprodil targeting GRIN-NDD, expanding global clinical program.
SAHPRA Accelerated Approval: What You Need to Know About Oncology Access
Learn how SAHPRA's Accelerated Approval is transforming oncology access, expediting vital treatments like Pembrolizumab for cancer patients in need.
FDA Accelerated Approval Pathway: Impact on Oncology Market Access & Pricing in 2026
This article examines how the FDA's Accelerated Approval Pathway will shape oncology market access and pricing strategies for cancer therapies in 2026.
Cancer Immunotherapies UAE: Regulatory and Access Insights 2025
This article provides essential insights into the regulatory landscape and access to cancer immunotherapies in the UAE, focusing on key drugs and future trends.
Saudi Arabian Pharmaceutical Market: Impact of SFDA's Accelerated Drug Approval
The Saudi Arabian pharmaceutical market is evolving rapidly due to the SFDA's accelerated drug approval process, enhancing access to essential medications.
ANVISA Approves Enhertu: Transforming HER2-Positive Breast Cancer Care in Brazil
Enhertu has received ANVISA approval, marking a significant advancement in the treatment landscape for HER2-positive breast cancer in Brazil.
Adaptive Clinical Trial Designs: Impact on FDA Approval Pathways & Timelines
This article delves into the role of adaptive clinical trial designs in expediting FDA approval pathways, focusing on drug XYZ for chronic pain management.
Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment
Ray Therapeutics' RTx-015 gene therapy receives EMA PRIME designation for retinitis pigmentosa, accelerating regulatory pathway for vision restoration treatment.
ANVISA Regulatory Changes 2026: Impact on Foreign Pharma Market Entry
Discover how ANVISA's 2026 regulatory changes will reshape the landscape for foreign pharmaceutical companies entering the Brazilian market.
SAHPRA Biosimilars Approval: Pathway Analysis and Market Implications
This article analyzes SAHPRA's biosimilars approval pathway and its market implications for biologics, impacting patient access to essential therapies.
NMPA Foreign Clinical Trial Data: What You Need to Know
This article explores the significance of NMPA foreign clinical trial data for drug approvals, focusing on its impact on cancer therapies and regulatory compliance.
Traditional Medicine in MEA Cancer Care: Evidence & Regulatory Insights 2024
This article delves into the integration of traditional medicine in cancer care across the MEA region, highlighting evidence and regulatory frameworks for effective treatment.
SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization
SQ Innovation announces CE marking for Lasix ONYU medical device under EU MDR, plus EMA centralized procedure eligibility for European market expansion.
PMDA SAKIGAKE Designation: Accelerating Innovative Drug Approvals in Japan
The PMDA SAKIGAKE Designation streamlines the approval process for innovative drugs, such as XYZ for cancer, fostering quicker patient access in Japan.
NMPA Approval Trends ADCs: Novel Lung Cancer Therapies in China 2025
Discover the latest NMPA approval trends for antibody-drug conjugates (ADCs) targeting lung cancer in China, focusing on innovative therapies expected by 2025.
PMDA SAKIGAKE Designation: Accelerating Rare Disease Therapy Approvals in Japan
The PMDA SAKIGAKE Designation fast-tracks the approval process for rare disease therapies, exemplified by XYZ Drug for ABC indication in Japan.
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
The SURPASS-CVOT trial results shed light on Mounjaro's cardiovascular safety, influencing its FDA labeling and future use in diabetes management.
Guerbet's Lipiodol Ultra Fluid Achieves EU Regulatory Milestone for Vascular Embolization Procedures
Guerbet announces positive EU regulatory outcome for Lipiodol Ultra Fluid in vascular embolization, expanding interventional radiology applications.